non-radiographic axial spondyloarthritis
Rheumatology · 2015–2024
11decisions
7medicines
3carried consumer input
6individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bimekizumab Treatment of adult patients with non-radiographic axial spondyloarthritis (nr-axSpA) who have failed to achieve adequate response to at least 2 NSAIDs or are… | Mar 2024 | Recommended with restriction | input received CreakyJoints Australia |
| ixekizumab Treatment of patients with non-radiographic ankylosing spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated CRP and/or… | Jul 2023 | Not recommended | none received |
| upadacitinib Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in adults with active disease who have inadequate response to NSAIDs. | Mar 2023 | Recommended with restriction | none received |
| secukinumab Requested amendment to increase maximum quantity from one to two injections and reduce repeats from five to two for the continuing treatment phase of… | Jul 2021 | Not recommended | none received |
| ixekizumab Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation (elevated CRP and/or MRI evidence) who… | Nov 2021 | Recommended with restriction | none received |
| secukinumab Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation (elevated CRP and/or MRI evidence) who have… | Nov 2020 | Recommended with restriction | none received |
| certolizumab pegol Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation (elevated C-reactive protein and MRI… | Nov 2019 | Recommended with restriction | none received |
| golimumab Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation (elevated CRP and/or MRI evidence) who have… | Jul 2018 | Recommended with restriction | 4 individuals |
| golimumab Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation who have had an inadequate response to, or… | Nov 2017 | Not recommended | 2 individuals |
| etanercept Treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adults with objective signs of inflammation (elevated C-reactive protein and/or MRI… | Mar 2016 | Not recommended | none received |
| etanercept Treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) who have had an inadequate response to NSAIDs, with objective signs of… | Mar 2015 | Not recommended | none received |
Who spoke
CreakyJoints Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.